title: Nitric oxide treatment reduces neo-intimal formation and modulates osteopontin expression in an ex-vivo human model of intimal hyperplasia.
abstract: In this study the effects of nitric oxide (NO) on intimal hyperplasia (IH) were evaluated in an ex-vivo model of human saphenous vein (SV). SV segments were cultured in conditions able to reproduce IH (FCS), or in medium alone (RPMI), or in presence of a NO donor (NO). Osteopontin (OPN) and Interleukin (IL)-6 were determined in the medium at different culture times and in the tissue, at the end of experiment. OPN and IL-6 release in medium was increased in FCS with respect to RPMI (OPN: 13.9+/-2.9 vs. 2.3+/-0.8 microg/ml, p=0.0011; IL-6: 304.2+/-64.7 vs. 42.0+/-10.1 ng/ml, p<0.0006) as well as intima thickness, that positively correlated with OPN production (r=0.81). In tissue OPN was higher in FCS (82.0+/-30.3 ng/mg protein) than in RPMI (13.8+/-4.2, p=0.0051) and at baseline (3.7+/-0.7, p=0.018). NO reduces IH progression (25%) and both OPN and IL-6 expression (OPN/GAPDH: undetectable baseline; 0.27+/-0.06 RPMI; 0.89+/-0.28 FCS; 0.09+/-0.05 NO; p=0.026 FCS vs. baseline, p=0.018 vs. RPMI, p=0.005 vs. NO). The beneficial NO effect on IH reduction appears to be mediated by the indirect inhibition of OPN production. NO could modulates the initial inflammatory signals that induces the OPN over-production with the related cascade of events leading to IH.
authors.affiliation: Scuola Superiore S. Anna, Pisa, Italy.
authors.forename: Chiara
authors.initials: C
authors.lastname: Colotti
authors.forename: Simona
authors.initials: S
authors.lastname: Vittorini
authors.forename: Virginia
authors.initials: V
authors.lastname: Ottaviano
authors.forename: Maristella
authors.initials: M
authors.lastname: Maltinti
authors.forename: Valeria
authors.initials: V
authors.lastname: Angeli
authors.forename: Silvia
authors.initials: S
authors.lastname: Del Ry
authors.forename: Daniela
authors.initials: D
authors.lastname: Giannessi
mesh_terms: D006083:Graft Occlusion, Vascular; D006801:Humans; D006965:Hyperplasia / Q000378:metabolism* / Q000473:pathology; D015850:Interleukin-6 / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism*; D020030:Nitric Oxide Donors / Q000494:pharmacology; D009603:Nitroso Compounds / Q000494:pharmacology; D053495:Osteopontin / Q000235:genetics / Q000378:metabolism*; D012501:Saphenous Vein / Q000033:anatomy & histology / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D015607:Stents; D046509:Tissue Culture Techniques; D017539:Tunica Intima / Q000033:anatomy & histology / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology*
chemical_list: D015850:Interleukin-6; D020030:Nitric Oxide Donors; D009603:Nitroso Compounds; D053495:Osteopontin; C094210:2,2'-(hydroxynitrosohydrazono)bis-ethanamine; D009569:Nitric Oxide